HSBC lifts Regeneron price target to $920
Analysts expect a potential two-year U.S. patent extension for Dupixent and HSBC raised its REGN price target to $920 with a Buy rating.
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.